Peptide questions · SLU-PP-332
SLU-PP-332 side effects: what studies and users report
Reviewed Evidence: EmergingPublished by PepVault
The library lists two common side effects for SLU-PP-332, no human safety data and unknown long-term effects, and a safety note; its research is mostly in animals and cells, so reports in people come from community use.
Its safety note opens: There is no human safety data: SLU-PP-332 has never been given to people in a published study, so its effects in people, short or long term, are unknown.
What is commonly reported with SLU-PP-332
- No human safety data
- Unknown long-term effects
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| No human safety data | None: listed for SLU-PP-332 alone |
| Unknown long-term effects | None: listed for SLU-PP-332 alone |

Model. Individual results vary.
Which SLU-PP-332 side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). None of SLU-PP-332’s 2 listed effects appears for another metabolic & GLP-1 compound: no human safety data and unknown long-term effects are its own in the library.
What the SLU-PP-332 safety notes say
The library’s safety note
There is no human safety data: SLU-PP-332 has never been given to people in a published study, so its effects in people, short or long term, are unknown. In mice, 10 days at 50 mg/kg twice daily by injection caused no overt toxicity, with normal blood counts, electrolytes and muscle enzymes. It is sold as a research chemical, so purity, dose and contents aren't regulated, and anti-doping labs are building tests for it: as a compound with no approval for human use, it falls under the World Anti-Doping Agency's ban on non-approved substances (S0), in force at all times. Discuss with your clinician.
The library’s interaction note
No interaction data exist. In human liver enzyme preparations it is broken down into many metabolites (doping-control studies), but which enzymes do it, and what that means alongside other medicines, hasn't been studied. Running it with other metabolic compounds (GLP-1 drugs, MOTS-c, 5-Amino-1MQ) is untested. Discuss all your medicines with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the SLU-PP-332 reports come from
The library rates the evidence on SLU-PP-332 as emerging: mostly preclinical, with limited human data.
Of the library’s 5 research notes on SLU-PP-332, 4 rest on animal studies and 1 on community reports.
Our 4 study pages on SLU-PP-332: 4 animal studies (mice).
So the effects listed for SLU-PP-332 come from people who have used it, not from a controlled trial in people.
Questions people ask
What are the side effects of SLU-PP-332?
The library lists two common side effects for SLU-PP-332, no human safety data and unknown long-term effects, and a safety note; its research is mostly in animals and cells, so reports in people come from community use.
Do SLU-PP-332’s side effects come from human studies?
The library rates the evidence on SLU-PP-332 as emerging, and its research is mostly in animals and cells, so reports in people come from community use.
Which SLU-PP-332 side effects are its own?
Among the metabolic & GLP-1 compounds, the library lists no human safety data and unknown long-term effects for SLU-PP-332 alone.
Does SLU-PP-332 interact with other medicines?
The library’s interaction note on SLU-PP-332 begins: No interaction data exist.